AstraZeneca Halts Phase III eVOLVE-Lung02 Trial of Volrustomig in Metastatic NSCLC
AZN is trading near its 52-week low of $141.772 (11% above the low).
Summary
AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in mNSCLC after an IDMC review found the combination unlikely to meet PFS or OS endpoints in PD-L1 negative patients.
Key Events · Product Development and Regulatory · AZN
-
Phase III Trial Discontinued
AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in mNSCLC with PD-L1 <50% based on IDMC recommendation.
-
Primary Endpoints Unlikely to Be Met
The IDMC concluded the volrustomig combination was unlikely to meet dual primary endpoints of progression-free survival or overall survival in PD-L1 negative (<1%) patients.
-
No New Safety Signals
Safety profile of volrustomig plus chemotherapy was consistent with known profiles of the individual medicines.
-
Other Volrustomig Trials Continue
Phase III trials of volrustomig continue as planned in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma.
Analysis · AZN · Life Sciences
AstraZeneca is stopping a Phase III trial for volrustomig in metastatic non-small cell lung cancer after an independent data monitoring committee determined the combination was unlikely to meet its primary endpoints. The trial enrolled 895 patients across 25 countries, and the decision removes a potential first-line indication in a large patient population. While the safety profile was consistent with known profiles, the discontinuation is a setback for the company's immuno-oncology pipeline, though other volrustomig trials in cervical cancer, head and neck cancer, and mesothelioma continue.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $156.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $242.6B. The 52-week trading range was $141.77 to $212.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.